Heart Failure With Reduced Ejection Fraction (HFrEF)SHARE-HFNCT07670845
Implementation of an Encounter-based Patient Decision Aid for Heart Failure Medications in Heart Function Clinics: the SHARE-HF Pragmatic, Stepped-wedge Trial
A study testing SHARE-HF decision aid in people with Heart Failure With Reduced Ejection Fraction (HFrEF), run by University of British Columbia.
Trial summary
The goal of this clinical trial is to learn if a shared decision-making tool called SHARE-HF can help more people with heart failure receive guideline-recommended medications. The study includes adults with a type of heart failure called heart failure with reduced ejection fraction (HFrEF), who attend heart function… Read more about this study
- Who is it for?
- Ages 40 to 85 years
- Conditions the study is for
- Heart Failure With Reduced Ejection Fraction (HFrEF)
- What is being tested?
- SHARE-HF decision aid
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,350 participants
- Where
- No sites listed yet
- Study dates
- 2 Nov 2026to 31 Oct 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient in a participating HF clinic;
- In-person initial HF clinic visit;
- Age 40-85 years;
- Heart failure with reduced ejection fraction (HFrEF), as indicated by latest cardiac imaging demonstrating ejection fraction ≤40%.
Who cannot join
- Previous request to the clinic not to be contacted for research;
- Consent opt-out;
- Non-BC residents;
- Residents of long-term care facilities or hospice;
- Receiving palliative care;
- End-stage kidney disease on dialysis or latest estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
The goal of this clinical trial is to learn if a shared decision-making tool called SHARE-HF can help more people with heart failure receive guideline-recommended medications. The study includes adults with a type of heart failure called heart failure with reduced ejection fraction (HFrEF), who attend heart function clinics in British Columbia, Canada. The main question it aims to answer is:
- Does use of SHARE-HF during clinic visits lead to more participants receiving their recommended heart failure medications after 6 months?
Read more
Researchers will compare clinics using the SHARE-HF tool to clinics providing usual care to see if the tool helps more participants get their recommended medications.
Participants will use the SHARE-HF web-based tool with their clinician during regular clinic visits. The tool shows participants how their heart failure may affect their health over time, explains their medication options, and helps them and their clinician make treatment decisions together.
- Being tested
- SHARE-HF decision aid
- Keywords
- shared decision-making, decision aid, encounter-based decision aid, guideline-directed medical therapy, GDMT
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SHARE-HF decision aidOther
Web-based, interactive decision aid that: (1) provides individualized prognosis based on a validated clinical prediction model; (2) presents evidence-based medication options aligned with guidelines; and (3) quantifies benefits and downsides across six patient-prioritized features.
| Study group | Role | What they receive |
|---|---|---|
| Intervention: Use of the SHARE-HF decision aid during clinic visits | Experimental | Not described Receives: Other: SHARE-HF decision aid |
| Usual care | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Efficacy-weighted HFrEF guideline-directed medical therapy (GDMT) score
Scores range from 0 to 8, with a higher score indicating greater (better) GDMT utilization.
Measured: 6 months
Secondary outcomes (4)
Worsening heart failure events
Measured: 1 year; 3 years
Adherence to HFrEF GDMT
Measured: 1 year; 3 years
Average percent concordance between prescribed and dispensed prescriptions for GDMT
Measured: 1 year
Utilization of individual HFrEF medication classes at any dose
Measured: Months 3, 6, and 12
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jun 2026
- Study start2 Nov 2026 (estimated)
- Primary completion30 Apr 2028 (estimated)
- Study completion31 Oct 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Heart Failure With Reduced Ejection Fraction (HFrEF)Studies of the same condition, open and under way.
- More trials run by University of British ColumbiaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Stepped-wedge cluster randomized trial
- Masking
- None (open label)
- Enrolment
- 1,350 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of British Columbia
- Sponsor type
- University, hospital or other
- Collaborators
- Providence Healthcare, Vancouver Coastal Health
- Responsible party
- Principal investigator, Ricky Turgeon, University of British Columbia
- Investigators
- Ricky D Turgeon, BSc(Pharm), ACPR, PharmD, Principal investigator, University of British Columbia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07670845
- Sponsor's protocol ID
- H26-01673
- Acronym
- SHARE-HF
- Status last verified
- Jun 2026
- First submitted
- 17 Jun 2026
- Last updated
- 26 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Implementation of an Encounter-based Patient Decision Aid for Heart Failure Medications in Heart Function Clinics: the SHARE-HF Pragmatic, Stepped-wedge Trial
- ClinicalTrials.gov ID
- NCT07670845
- Acronym / sponsor ID
- SHARE-HF / H26-01673
- Keywords
- shared decision-making, decision aid, encounter-based decision aid, guideline-directed medical therapy, GDMT
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 1,350 participants (estimated)
- Lead sponsor
- University of British ColumbiaUniversity, hospital or other
- Collaborators
- Providence Healthcare, Vancouver Coastal Health
- Study start
- 2 Nov 2026 (estimated)
- Primary completion
- 30 Apr 2028 (estimated)
- Study completion
- 31 Oct 2030 (estimated)
- First posted
- 26 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if a shared decision-making tool called SHARE-HF can help more people with heart failure receive guideline-recommended medications. The study includes adults with a type of heart failure called heart failure with reduced ejection fraction (HFrEF), who attend heart function clinics in British Columbia, Canada. The main question it aims to answer is:
- Does use of SHARE-HF during clinic visits lead to more participants receiving their recommended heart failure medications after 6 months?
Researchers will compare clinics using the SHARE-HF tool to clinics providing usual care to see if the tool helps more participants get their recommended medications.
Participants will use the SHARE-HF web-based tool with their clinician during regular clinic visits. The tool shows participants how their heart failure may affect their health over time, explains their medication options, and helps them and their clinician make treatment decisions together.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Stepped-wedge cluster randomized trial
| Arm | Type | Receives |
|---|---|---|
| Intervention: Use of the SHARE-HF decision aid during clinic visits | Experimental | Other: SHARE-HF decision aid |
| Usual care | No intervention | – |
Who may qualify
- Ages
- 40 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Patient in a participating HF clinic;
- In-person initial HF clinic visit;
- Age 40-85 years;
- Heart failure with reduced ejection fraction (HFrEF), as indicated by latest cardiac imaging demonstrating ejection fraction ≤40%.
Key exclusion criteria (6 listed)
- Previous request to the clinic not to be contacted for research;
- Consent opt-out;
- Non-BC residents;
- Residents of long-term care facilities or hospice;
- Receiving palliative care;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SHARE-HF decision aidWeb-based, interactive decision aid that: (1) provides individualized prognosis based on a validated clinical prediction model; (2) presents evidence-based medication options aligned with guidelines; and (3) quantifies benefits and downsides across six patient-prioritized features. | Other | Intervention: Use of the SHARE-HF decision aid during clinic visits |
Primary outcome
Efficacy-weighted HFrEF guideline-directed medical therapy (GDMT) score
Time frame: 6 months
Scores range from 0 to 8, with a higher score indicating greater (better) GDMT utilization.
4 secondary outcomes
Worsening heart failure events
Time frame: 1 year; 3 years
Adherence to HFrEF GDMT
Time frame: 1 year; 3 years
Average percent concordance between prescribed and dispensed prescriptions for GDMT
Time frame: 1 year
Utilization of individual HFrEF medication classes at any dose
Time frame: Months 3, 6, and 12
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Heart Failure With Reduced Ejection Fraction (HFrEF)
Recruiting
Achieving Optimal Medical Therapy Through Percutaneous Treatment of Secondary Mitral Regurgitation to Improve Outcome in Patients With HFrEF
Mitral Regurgitation Functional, Heart Failure With Reduced Ejection Fraction (HFrEF)
Not yet recruitingObservational study
Real-world Effectiveness and Safety of Savagen (Sacubitril/Valsartan) in Malaysian HFrEF Patients
Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure
Recruiting
Vsling™ III: Clinical Evaluation of the Vsling™ Device for Ventricular Repair in Patients With Heart Failure
HFrEF - Heart Failure With Reduced Ejection Fraction
RecruitingPhase 4
Pharmacological Optimization in Prevention in Heart Failure: A Sex-gap?
Heart Failure, Acute Heart Failure
Recruiting
Olive Oil Supplementation for Heart Failure With Reduced Ejection Fraction
Heart Failure With Reduced Ejection Fraction (HFrEF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ricky D Turgeon, BSc(Pharm), ACPR, PharmD principal investigator
University of British Columbia
Questions about this trial
What is this clinical trial studying?
A study testing SHARE-HF decision aid in people with Heart Failure With Reduced Ejection Fraction (HFrEF), run by University of British Columbia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 26 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ricky D Turgeon, BSc(Pharm), ACPR, PharmD (236-777-6961, ricky.turgeon@ubc.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Efficacy-weighted HFrEF guideline-directed medical therapy (GDMT) score (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jun 2026; AzTrials last refreshed its copy on 6 Nov 2026.